Mechanism and Regulation of Nonhomologous DNA End Joining
Mechanism and Regulation of Nonhomologous DNA End Joining
批准号:
7942230
负责人:
MICHAEL R LIEBER
金额:
$15.79万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2015-01-31
关键词:
AffectAgeAgingBRCT DomainBindingCancer EtiologyCellsChemicalsChromosomal translocationChromosome PairingComplexDNADNA DamageDNA Double Strand BreakDNA RepairDNA Repair PathwayDNA SequenceDNA StructureDNA ligase IVDNA-PKcsDNA-Protein InteractionDevelopmentEnzymesFree RadicalsHistonesHumanIonizing radiationKu ProteinLengthLigaseLigationMalignant NeoplasmsMediatingModificationMutationNonhomologous DNA End JoiningPathway interactionsPolymerasePositioning AttributePriceProcessPropertyProteinsRadiationRadiation-Sensitizing AgentsRegulationSiteSomatic CellSystemTailTestingTherapeuticTimeVariantVertebral columnVertebratesWorkX-Ray Crystallographyartemischemotherapyflexibilityhomologous recombinationimprovedin vivoinhibitor/antagonistinorganic phosphateinsightmutantnucleasephosphodiesterpublic health relevancereconstitutionrepairedsmall moleculespatial relationshipstoichiometry
中文摘要
描述(由申请人提供):双链DNA断裂(DSBs)每天在所有细胞中发生多次。同源重组(HR)和非同源DNA末端连接(NHEJ)是修复dsb的两种主要途径。然而,NHEJ是更普遍的途径,因为它不需要同源供体,而且NHEJ具有足够的灵活性,可以连接几乎任何一对不相容的DNA末端。NHEJ的灵活性是必不可少的,因为dsb的自然原因(电离辐射、自由基、酶功能障碍)产生具有不同化学和结构构型的DNA末端。因此,这种灵活性非常适合这项任务,但我们为这种灵活性付出的代价是,NHEJ在其发挥作用的大多数位点(在人类和其他脊椎动物中)导致DNA序列改变。因此,NHEJ产生导致癌症的体细胞突变,并可能导致衰老。NHEJ的灵活性代表了最复杂的蛋白质之一:DNA相互作用途径。虽然我们知道大多数参与NHEJ的蛋白质,并且从广义上知道它们的作用,但我们并不清楚它们是如何一起起作用的,它们的空间结构,或者它们的时间关系。有了更清晰的人类NHEJ的机制和结构图,我们将能够开发出可能用于治疗癌症的小分子抑制剂(作为化疗或辐射增敏剂)。本提案的目的1和2集中在NHEJ蛋白之间以及与DNA末端的结构和空间关系的问题上。目的3验证了NHEJ连接酶复合物对于在NHEJ过程中进行关键的端到端接触很重要的假设。目标4描述了一个更健壮的NHEJ重构的发展。在目标4中,该系统随后通过测试活性增强来识别任何剩余的NHEJ因子。目的5描述了组蛋白八聚体如何影响NHEJ的核酸酶、聚合酶和连接酶活性的分析。这些研究将显著提高我们对NHEJ如何参与对癌症病因至关重要的染色体易位等过程的理解,以及如何将NHEJ制成“可药物”用于治疗目的。
英文摘要
DESCRIPTION (provided by applicant): Double-strand DNA breaks (DSBs) occur in all cells multiple times per day. Homologous recombination (HR) and nonhomologous DNA end-joining (NHEJ) are the two primary pathways for repairing DSBs. However, NHEJ is the more general pathway because it does not require a homologous donor, and NHEJ is sufficiently flexible that it can join almost any pair of incompatible DNA ends. The flexibility of NHEJ is essential because natural causes of DSBs (ionizing radiation, free radicals, enzyme malfunction) generate DNA ends with diverse chemical and structural configurations. Hence, that flexibility is well-suited for the task, but the price that we pay for that flexibility is that NHEJ causes DNA sequence changes at most sites where it functions (in humans and other vertebrates). Hence, NHEJ generates somatic cell mutations that cause cancer and likely contribute to aging. The flexibility of NHEJ represents one of the most sophisticated protein:DNA interaction pathways. Though we know most of the proteins that participate in NHEJ and know, in broad terms, what they do, we do not have a clear picture of how they function together, their spatial configuration, or the temporal relationships. With a clearer mechanistic and structural picture of human NHEJ, we will be in a position to develop small molecule inhibitors that may be useful for treating cancer (as chemotherapy or as a radiation sensitizer). Aims 1 and 2 of this proposal focus precisely on the issues of structural and spatial relationships among the NHEJ proteins and with the DNA ends. Aim 3 tests the hypothesis that the NHEJ ligase complex is important for making key end-to-end contacts during NHEJ. Aim 4 describes development of a more robust NHEJ reconstitution. In Aim 4, that system is then used to identify any remaining NHEJ factors by testing for enhancement of activity. Aim 5 describes analysis of how histone octamers influence the nuclease, polymerase, and ligase activities of NHEJ. These studies will markedly improve our understanding of how NHEJ participates in processes such as chromosomal translocations that are of key importance in cancer etiology and how NHEJ might be made 'druggable' for therapeutic purposes.
PUBLIC HEALTH RELEVANCE: This project would clarify our insights into one of the key pathways for the repair of DNA damage. These insights will allow us to understand how some of the DNA damage that causes cancer and aging occurs. The benefits of some chemotherapy and therapeutic radiation work can be increased by this deeper level of understanding of this key DNA repair pathway.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of Human Lymphoid Chromosomal Translocation
-
批准号:10219165
-
项目类别:
-
资助金额:$37.74万
-
财政年份:2016
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanisms of Human Lymphoid Chromosomal Translocation
-
批准号:9756315
-
项目类别:
-
资助金额:$36.61万
-
财政年份:2016
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanisms of Human Lymphoid Chromosomal Translocation
-
批准号:9099617
-
项目类别:
-
资助金额:$37.74万
-
财政年份:2016
-
负责人:MICHAEL R LIEBER
-
依托单位:
Site-Specific Recombination in Human Health & Disease
-
批准号:10400938
-
项目类别:
-
资助金额:$42.9万
-
财政年份:2016
-
负责人:MICHAEL R LIEBER
-
依托单位:
Site-Specific Recombination in Human Health & Disease
-
批准号:10162067
-
项目类别:
-
资助金额:$42.9万
-
财政年份:2016
-
负责人:MICHAEL R LIEBER
-
依托单位:
Site-Specific Recombination in Human Health & Disease
-
批准号:10618161
-
项目类别:
-
资助金额:$42.9万
-
财政年份:2016
-
负责人:MICHAEL R LIEBER
-
依托单位:
Selective Inhibitors of the Artemis Endonuclease
-
批准号:8420339
-
项目类别:
-
资助金额:$3.98万
-
财政年份:2012
-
负责人:MICHAEL R LIEBER
-
依托单位:
Selective Inhibitors of the Artemis Endonuclease
-
批准号:8261909
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2012
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanism and Regulation of Nonhomologous DNA End Joining
-
批准号:8894424
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOINING
-
批准号:6596588
-
项目类别:
-
资助金额:$32.54万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanism and Regulation of Nonhomologous DNA End Joining
-
批准号:8111276
-
项目类别:
-
资助金额:$34.47万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOINING
-
批准号:6921450
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanism and Regulation of Nonhomologous DNA End Joining
-
批准号:8709816
-
项目类别:
-
资助金额:$33.43万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanism and Regulation of Nonhomologous DNA End Joining
-
批准号:8225268
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanism and Regulation of Nonhomologous DNA End Joining
-
批准号:8484352
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOINING
-
批准号:6763043
-
项目类别:
-
资助金额:$32.54万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOINING
-
批准号:7115723
-
项目类别:
-
资助金额:$31.78万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
Mechanism and Regulation of Human Nonhomologous DNA End Joining
-
批准号:10200683
-
项目类别:
-
资助金额:$39.19万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOINING
-
批准号:7266333
-
项目类别:
-
资助金额:$30.85万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOINING
-
批准号:7475161
-
项目类别:
-
资助金额:$30.76万
-
财政年份:2003
-
负责人:MICHAEL R LIEBER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: